FAM197Y3

Across TCGA pan-cancer cohorts, FAM197Y3 RNA is linked to patient survival in 5 of 34 cancer types, making it the most broadly survival-associated FAM197Y3 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher FAM197Y3 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated FAM197Y3 expression acts as an unfavorable survival marker.

LIHC, BLCA, and KIRC are the cancer types where FAM197Y3 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	III,IV	0.196	0.654	.005	45	view →
BLCA	DFS	Tertile	All	0.250	0.523	.032	36	view →
KIRC	OS	Tertile	All	0.451	0.666	.027	27	view →
SKCM	DFS	Tertile	All	0.058	0.757	<.001	27	view →
SARC	OS	Tertile	All	0.230	0.604	.027	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FAM197Y3–LIHC (OS)

Open the LIHC breakdown →